Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2021-03-25 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
2020年募集资金年度存放与使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the management, storage, and actual use of funds raised by the company through stock issuance in 2020. It references regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange, includes detailed financial tables on funds raised and used, and discusses compliance with regulatory guidelines. The document is titled as a "专项报告" (special report) on the storage and actual use of raised funds for the year 2020. This type of report is specifically related to capital raising activities and the use of proceeds, which aligns with the category of Capital/Financing Update (CAP). The document is substantive, contains financial data, and is not merely an announcement or certification. Therefore, the appropriate classification is CAP.
2021-03-25 Chinese
关于召开2020年度股东大会的通知
AGM Information Classification · 100% confidence The document is a detailed notice about the convening of the 2020 Annual General Meeting (AGM) of shareholders for 贝达药业股份有限公司 (Betta Pharmaceuticals Co., Ltd.). It includes information about the meeting date, time, location, voting procedures (both in-person and online), agenda items to be discussed and voted on (including the 2020 annual report, financial statements, profit distribution plan, and other corporate governance matters), and instructions for shareholder registration and proxy voting. The document does not contain the actual annual report or financial statements but rather serves as a formal notification to shareholders about the upcoming AGM and the matters to be considered. This fits the definition of AGM Information (AGM-R), which includes presentations and materials shared during the Annual General Meeting, or notices about the AGM. The document length (5723 characters) and content confirm it is not a brief announcement but a full AGM notice with detailed procedural information. Therefore, the correct classification is AGM Information (AGM-R).
2021-03-25 Chinese
2020年度独立董事工作报告（汪炜)
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's 2020 Annual Work Report" for Betta Pharmaceuticals Co., Ltd. It details the independent director's attendance at board meetings, opinions on various company proposals, committee work, investigations, investor protection efforts, training, and special powers exercised during the year 2020. The content focuses on the independent director's duties and activities rather than presenting financial statements or audit results. It is a detailed report on board/management activities and governance from the perspective of an independent director. The document length is 3693 characters, which is relatively short but contains substantive content about board and management activities rather than just an announcement or certification. Therefore, it fits best under Board/Management Information (MANG) as it relates to the independent director's report on their role and activities within the board and management structure.
2021-03-25 Chinese
2020年度关联方占用资金情况专项报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审计说明" (Special Audit Explanation) for the year 2020, issued by an accounting firm (立信会计师事务所) and addressed to the shareholders of 贝达药业股份有限公司. It includes detailed tables about non-operating fund occupation and related party fund transactions for 2020, with references to audited financial statements and compliance with regulatory notices from the China Securities Regulatory Commission and State-owned Assets Supervision and Administration Commission. The document contains audit findings and a special report on related party transactions, but it is not a full annual report or interim report. It is a standalone audit-related report focusing on specific audit matters related to non-operating fund occupation and related party transactions. The length is 2527 characters, which is relatively short but contains substantive audit information. This fits the definition of an Audit Report / Information (AR) rather than a full Annual Report (10-K) or a simple announcement. Therefore, the correct classification is AR with high confidence. FY 2020
2021-03-25 Chinese
关于巴替利单抗注射液（PD-1抗体）药品临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Betta Pharmaceuticals regarding the acceptance of a clinical trial application for a PD-1 antibody drug by the National Medical Products Administration (China's drug regulatory authority). It includes details about the drug, regulatory acceptance, and risk warnings. The document is short (1297 characters) and is an announcement of a regulatory event rather than a financial report or detailed filing. It does not contain financial data, management changes, voting results, or other report types. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about a clinical trial application acceptance, which does not fit other specific categories.
2021-03-24 Chinese
关于股东股份质押的公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from a company regarding the pledge of shares by a shareholder. It details the number of shares pledged, the proportion of shares involved, the pledge period, and the pledgee. The document is relatively short (1602 characters) and focuses on a specific shareholder's share pledge event. There is no financial report, earnings data, or management discussion. It is not an annual or interim report, nor a call transcript or governance document. The content fits the category of a capital or financing update, as it relates to changes in the company's capital structure through share pledging by a shareholder. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2021-03-22 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.